By studying the expression of genes, IntegraGen aims to better predict survival outcomes and the potential for cancer recurrence in patients with hepatocelluar carcinoma (liver cancer) and to identify differing subgroups of patients where targeted therapies are more effective.

55 Gene molecular signature

IntegraGen is developing a molecular signature comprised of 55 genes based on original research by Jessica Zucman-Rossi, M.D., Ph.D., Professor of Medicine, Oncology, University Paris Descartes, Hopital Européen Georges Pompidou and Head of the INSERM unit on Functional Genomics of Solid Tumors in Paris. The signature is comprised of a set of 55 genes that allow the distinction between benign and malignant liver tumors and their different histological subtypes.

5 Gene prognostic signature

Liver cancer signatureA 5 gene subset of the molecular signature identifies the prognosis and early tumor recurrence in patients diagnosed with HCC and treated by surgical resection. This signature has been validated in European, US and Asian patient cohorts with the authors reporting that the signature had better predictive accuracy than other gene expression signatures identified to date for patients with liver cancer. The prognostic information from this signature are independent of cirrhotic ground, tumor size and pathological features and may also be helpful towards defining appropriate patients for transplantation.

16 Gene molecular classification signature

A second set of 16 genes can be used to classify patients with hepatocellular carcinoma (HCC) into six distinct molecular groups. This subset of genes has the potential to aid researchers studying newer drugs for HCC to identify patients who may preferentially respond to these therapies.

Peer-Reviewed Publications